Trial Information

Summary: Research Study of an Antibody Treatment for Alzheimer’s Disease

We are seeking Alzheimer's Disease (AD) patients to evaluate the tolerability and safety of a new investigational drug called AAB-001 that may be a possible treatment for Alzheimer’s disease. AAB-001 is an investigational drug not currently approved by the U.S. Food and Drug Administration (FDA). Subjects will be randomly assigned to receive drug or placebo (contains no active medication). Subjects must have a study partner or caregiver who is able to come to 11 clinic visits over the course of 16 weeks. Study participants will be reimbursed for parking. If you are interested, please email Dr. Gad Marshall gamarshall@partners.org or call Brigham and Women’s Hospital at (617) 732-8085. All information is kept completely confidential.


Inclusion criteria:

1. 50 years of age or older
2. Diagnosis of mild to moderate Alzheimer's Disease, MMSE 16 to 26
3. Have been on stable doses of FDA-approved treatments such as Aricept, Reminyl, Exelon, and/or Namenda (memantine) for at least 60 days.

Exclusion criteria:

1.Significant neurological disease other than Alzheimer’s disease
2.Clinically significant and/or uncontrolled medical condition
3.Use of an investigational drug within 30 days prior to the screening visit or during the entire study.
4.Previous treatment with immunotherapy for AD

If you would like to learn more about participating in this study, please send an e-mail message using the form below.